CClinicalTrials.gg
CompletedNCT03290261HYPNOCYSTUpdated Jun 26, 2023

Hypnosis as a Therapeutic Tool in Patients With Reccurent Cystitis

An interventional study of Hypnosis in Reccurent Cystitis, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Half of the women present an episode of cystitis once in their lives. A recurrence occurs in about 20% to 30% of the patients, and half of these patients will make more than 4 episodes per year, defining recurrent cystitis (CR).

Complications such as pyelonephritis are rare (less than 0.5% of patients in the absence of underlying complication), however, CRs are responsible for a significant impact on women but also on society. Pain is at the forefront, but also the fear of not managing pollakiuria, with its social exclusion. The impact on sexuality is major. The medical circuit imposed on the patients is long and arduous. The clinical assessment sometimes reveals favorable factors, variable in pre- or post-menopause, but in the majority of cases, no explanatory cause can resolve the problem and some authors suggest resignation as a classic reaction to this problem. The only study on psychological disorders associated with recurrent cystitis suggests patients who are much more anxious than the average of female.

Hypnotherapy is an old technique, used for care in Western societies for at least two hundred years. By the word, the practitioner induces in the patient a particular state of consciousness characterized by an indifference on the outside and a hyper suggestibility. This "hypnotic" state of consciousness can be used to amplify the patient's internal resources to fight against anxiety and pain, and to eliminate symptoms.

The physiological mechanisms at work in hypnosis are the subject of recent studies becoming more and more precise. The results of these studies made it possible to objectify changes in cerebral functioning related to hypnotic trance.

A report by Inserm of 2015 confirms the effectiveness of this practice in hypnosedation, hypnoanalgesia and hypnotherapy, particularly in irritable bowel syndrome, although the methodology to be used in its evaluation is difficult and subjective. The principal investigator hypothesizes that the symptoms presented in recurrent cystitis (pain, anxiety) can be improved by hypnotherapy, and that thus the prognosis of this pathology can be totally modified.

In the absence of any study published in the literature, the investigator propose an intervention pilot study with minimal risks and constraints monocentric prospective non-randomized prospectively in 15 patients.

The main objective of this project is to demonstrate that hypnotherapy improves the psycho-emotional parameters of patients suffering from recurrent cystitis after 3 hypnosis sessions combined with home exercises performed by the patient. The evaluation will be carried out during the last session of hypnosis.

02

Conditions studied

  • Reccurent Cystitis

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women aged at least 18 years
  • Affiliated to social security
  • Presenting recurrent cystitis defined by a frequency of more than 4 episodes per year, and alleging stress, pain, impaired quality of life or anxiety related to this condition.
  • Available to perform 3 hypnosis sessions of one hour to 4/6 weeks apart and to perform home task prescriptions (self-hypnosis or hearing of a recorded medium).
  • Having previously been explored according to good practice and informed with the tool created by the RéSO InfectiO PACA Est, with a 3 months follow-up compared to this initial consultation.
  • Having signed informed consent.
  • Patient under tutelage, under curatorship, protected by the law

Exclusion criteria

Exclusion Criteria:

  • Pregnant women (declarative because no theoretical contraindication, but different care)
  • Other nonpharmacological treatments (acupuncture, cognitive and behavioral therapy, sophrology ...)
  • Treatment with psychotropic drugs modified for less than six months
  • Severe visceral deficiencies in the previous year.
  • Individual psychiatric pathology
  • Other progressive infectious diseases requiring antibiotic treatments
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Patients with reccurent cystitis

    Patient perform 3 hypnosis sessions

    Other: Hypnosis

Interventions

  • OtherHypnosis

    3 hypnosis sessions performed at 4 - 6 weeks apart

05

What researchers measure

Primary outcomes

  1. Score at HAD Scale

    Overall score at the HAD scale at the end of treatment ie M3, compared to the initial score.

    Time frame: Month 3

Secondary outcomes

  1. Score at Pain evaluation scale

    Overall score at the Pain evaluation scale at the end of treatment ie M3, compared to the initial score.

    Time frame: Month 3

  2. Evolution of HAD scale score

    Time frame: Month 12

  3. Evolution of Pain evaluation scale score

    Time frame: Month 12

  4. Patient satisfaction

    Patient satisfaction will be assessed on a simple numerical scale of 1 to 10 at the end of treatment

    Time frame: Month 12

  5. Ability to manage the symptoms

    The ability to manage their symptoms sera evaluated by a semantic scale at the end of treatment

    Time frame: Month 12

  6. Sexuality evaluation

    Assessment of the performance in charge of sexuality serum evaluation of the overall semantic scale and on the specific improvement of 2 criteria: anxiety of the sexual act, comfort (dyspareunia) during the act.

    Time frame: Month 12

  7. Consumption of heath care

    Consumption of health care compared to the previous year (medical consultations for cystitis, number of laboratory tests, antibiotics or analgesics, work stoppage)

    Time frame: Month 12

06

Study locations

1 site
  • Hôpital Archet
    Nice, 06202, France
07

Registry details

Key details

Study ID
NCT03290261
Lead sponsor
Centre Hospitalier Universitaire de Nice
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Aug 8, 2017
Primary completion
Oct 29, 2019
Completion
Oct 29, 2020
Last update
Jun 26, 2023

Study contacts

Véronique Mondain, PH
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion